Nemaura Medical (Nasdaq:NMRD) announced today that it received Saudi Food and Drug Authority (SFDA) approval for its sugarBEAT sensor.
The company develops daily, non-invasive, disposable, wearable glucose sensors. It also offers digital diabetes management tools and earlier this year added CGM-guided insulin dose titration to its offerings.
Nemaura’s sugarBEAT, a CE-marked device, offers non-invasive, flexible continuous glucose monitoring (CGM). It provides actionable insights derived from real-time glucose measurements and daily glucose trend data. It could help people with diabetes and pre-diabetes better manage, reverse and prevent the onset of the chronic condition.
Loughborough, England-based Nemaura submitted an FDA premarket approval application for sugarBEAT in the U.S.
Get the full story at our sister site, Drug Delivery Business News.